Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Avastin plus chemotherapy showed doubling of time without cancer progression
June 16th, 2005
Genentech, Inc., (DNA) and Roche (SWX) announced that a phase III study (E2100) of Avastin (bevacizumab) plus paclitaxel chemotherapy in first-line metastatic breast cancer met its primary efficacy endpoint of improving progression-free survival (PFS), compared to chemotherapy alone. Results from an interim analysis of this study showed that patients receiving Avastin plus paclitaxel doubled the duration of surviving without cancer progression compared to paclitaxel alone (or a hazard ratio of 0.50, which is equivalent to a 50% reduction in the risk of cancer progression). Median progression-free survival was 11 months for patients treated with...
Source: Women's Health Weekly (2005-06-16)
|
